These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 25098288)
21. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Duraiswamy J; Freeman GJ; Coukos G Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756 [TBL] [Abstract][Full Text] [Related]
22. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Chen J; Jiang CC; Jin L; Zhang XD Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673 [TBL] [Abstract][Full Text] [Related]
23. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Frydenlund N; Mahalingam M Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003 [TBL] [Abstract][Full Text] [Related]
24. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Mamalis A; Garcha M; Jagdeo J Arch Dermatol Res; 2014 Aug; 306(6):511-9. PubMed ID: 24615548 [TBL] [Abstract][Full Text] [Related]
25. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Balar AV; Weber JS Cancer Immunol Immunother; 2017 May; 66(5):551-564. PubMed ID: 28213726 [TBL] [Abstract][Full Text] [Related]
26. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Majidpoor J; Mortezaee K Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590 [TBL] [Abstract][Full Text] [Related]
31. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968 [TBL] [Abstract][Full Text] [Related]
32. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma. Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514 [TBL] [Abstract][Full Text] [Related]
33. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine. Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253 [TBL] [Abstract][Full Text] [Related]
34. PD-1 signaling pathway in sepsis: Does it have a future? Chen R; Zhou L Clin Immunol; 2021 Aug; 229():108742. PubMed ID: 33905818 [TBL] [Abstract][Full Text] [Related]
35. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. Haile ST; Horn LA; Ostrand-Rosenberg S Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296 [TBL] [Abstract][Full Text] [Related]
36. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Diskin B; Adam S; Cassini MF; Sanchez G; Liria M; Aykut B; Buttar C; Li E; Sundberg B; Salas RD; Chen R; Wang J; Kim M; Farooq MS; Nguy S; Fedele C; Tang KH; Chen T; Wang W; Hundeyin M; Rossi JAK; Kurz E; Haq MIU; Karlen J; Kruger E; Sekendiz Z; Wu D; Shadaloey SAA; Baptiste G; Werba G; Selvaraj S; Loomis C; Wong KK; Leinwand J; Miller G Nat Immunol; 2020 Apr; 21(4):442-454. PubMed ID: 32152508 [TBL] [Abstract][Full Text] [Related]
37. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Ai L; Xu A; Xu J Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706 [TBL] [Abstract][Full Text] [Related]
38. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
39. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197 [TBL] [Abstract][Full Text] [Related]
40. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Wang Y; Wu L; Tian C; Zhang Y Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]